759 related articles for article (PubMed ID: 28465492)
1. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic cancer therapy with a vaccinia virus strain.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B; Hu Z
Oncol Rep; 2019 Jan; 41(1):686-692. PubMed ID: 30365140
[TBL] [Abstract][Full Text] [Related]
4. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
5. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
6. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
7. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma.
Deng L; Yang X; Ding Y; Fan J; Peng Y; Xu D; Huang B; Hu Z
Virol J; 2022 Mar; 19(1):44. PubMed ID: 35292065
[TBL] [Abstract][Full Text] [Related]
9. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
10. IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer.
Deng L; Yang X; Fan J; Ding Y; Peng Y; Xu D; Huang B; Hu Z
Oncol Res; 2021 Mar; 28(6):579-590. PubMed ID: 32641200
[TBL] [Abstract][Full Text] [Related]
11. Bioluminescence imaging of a tumor-selective, thymidine kinase-defective vaccinia virus Guang9 strain after intratumoral or intraperitoneal administration in mice.
Ding Y; Fan J; Deng L; Peng Y; Zhang J; Huang B
Oncotarget; 2017 Oct; 8(51):88708-88718. PubMed ID: 29179469
[TBL] [Abstract][Full Text] [Related]
12. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.
Gentschev I; Müller M; Adelfinger M; Weibel S; Grummt F; Zimmermann M; Bitzer M; Heisig M; Zhang Q; Yu YA; Chen NG; Stritzker J; Lauer UM; Szalay AA
PLoS One; 2011; 6(7):e22069. PubMed ID: 21779374
[TBL] [Abstract][Full Text] [Related]
13. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
[TBL] [Abstract][Full Text] [Related]
14. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
15. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
[TBL] [Abstract][Full Text] [Related]
16. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.
Chen NG; Yu YA; Zhang Q; Szalay AA
J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Tumor Specificity and Immunity of Thymidine Kinase-Deleted Vaccinia Virus Guang9 Strain.
Ding Y; Fan J; Deng L; Peng Y; Zhou B; Huang B
Onco Targets Ther; 2020; 13():7683-7697. PubMed ID: 32801778
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
[TBL] [Abstract][Full Text] [Related]
19. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
20. Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.
Hughes J; Wang P; Alusi G; Shi H; Chu Y; Wang J; Bhakta V; McNeish I; McCart A; Lemoine NR; Wang Y
Gene Ther; 2015 Jun; 22(6):476-84. PubMed ID: 25876464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
